Menu
Menu
Dr. Arantxa Hervás, CGT Dx Director at Vitrolife Group, shares how her team modernized carrier screening across a global network processing over 1,300 samples per month, moving toward a more harmonized approach to expanded carrier screening (CGT).
She walks through Vitrolife's partnership with SOPHiA GENETICS and adoption of the SOPHiA DDM™ Enhanced Clinical Exome Solution, which cut turnaround time from 21 to 15 days and reduced complementary testing from 11 assays to 4, while strengthening detection of complex variants and CNVs in line with ACMG standards.
Watch the recording for implementation learnings and the outcomes Vitrolife has achieved since unifying its workflow.
Speaker
Dr. Arantxa Hervas Lorente, Ph.D
CGT Dx Director, Vitrolife Group
SOPHiA DDM™ Enhanced Exome Solutions are for Research Use Only (RUO); RUO results must not be used for clinical diagnosis or patient management.
BOSTON and SALT LAKE CITY - October 8, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.
Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice® CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.”
As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad’s PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS’ technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries.
“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. “By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.”
Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer
Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDMTM, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
SOPHiA GENETICS Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Investor Contacts
Kellen Sanger
[email protected]
Matt Scalo
(801) 584-3532
[email protected]
Media Contacts
Sarah Mack
[email protected]
Andria Rosell
(385) 202-3510
[email protected]
Most hereditary cancer NGS workflows are built to catch SNVs and indels. But copy number variations (CNVs) can be just as clinically significant, and far easier to miss, particularly in genes like PALB2, where large deletions are more common than many realise.
What began as a straightforward hereditary cancer study led somewhere no one expected. Dr. Elena Tenedini (Associate Professor at University Hospital of Modena) and colleagues compared variants from nearly 3,000 patients against published cohorts. When they reached the CNV data, PALB2 emerged as a leading contributor of pathogenic CNVs, driven largely by a recurrent exon 11 deletion clustered in one region of Italy. Collaboration with the University of Florence pointed to a shared, relatively recent origin.
None of this would have surfaced without analysing CNVs and SNVs/indels together. In this on-demand webinar, hosted by Front Line Genomics, Dr. Tenedini shows how her laboratory built a single NGS workflow with the SOPHiA DDM™ Dx Hereditary Cancer Solution, and how integrated analysis uncovers patterns researchers didn't know to look for.
What you'll learn:
Stay for the Q&A
Dr. Tenedini answers audience questions on founder variants in the clinic, follow-up for families with the PALB2 variant, why CNVs are underreported, and the future of hereditary cancer testing, from long-read sequencing to newer reference genomes.
Speakers:
Dr. Elena Tenedini
Associate Professor
University Hospital of Modena
Sevena Yaghoubian, MBA
Senior Director, Genomics
SOPHiA GENETICS
Next-generation sequencing (NGS) has transformed the diagnosis and management of haematologic malignancies, providing increasingly detailed insights into the molecular drivers of disease. However, many workflows continue to rely on single time point genomic assessments, limiting opportunities to leverage sequencing data throughout the patient journey.
In this webcast, Dr Todd Knepper of Moffitt Cancer Center will share lessons from a molecular tumour board and discuss how genomic information can support decision-making beyond initial diagnosis. Drawing on clinical experience and real-world examples, he will explore the role of NGS for risk assessment, monitoring clonal evolution, post-transplant surveillance and the interpretation of complex molecular findings.
He will also examine the challenges posed by clonal haematopoiesis of indeterminate potential (CHIP) and the importance of multidisciplinary approaches to genomic interpretation. Attendees will gain insight into emerging strategies for identifying and monitoring high-risk cases, and how expanded NGS applications might help to integrate precision oncology more effectively into routine haematology practice.
Learn:
Speakers:
Todd Knepper
Associate Member, Precision Oncology
Department of Pathology, Moffitt Cancer Center
Moderator:
Nikki Forrester
Freelance Science Writer and Editor
Large hospitals face a widening gap: guidelines are moving faster than most labs can validate against. And legacy PCR- and FISH-based workflows, however reliable, weren't built to scale to that pace. Prof. Klaus Schmetterer, Head of the Molecular Diagnostics Department, and his team at the Medical University of Vienna, Austria, one of Europe's largest tertiary care centers, are closing that gap.
In this session, Prof. Schmetterer shows how his team unlocked roughly 12 times more genomic coverage, at a comparable cost, without slowing down the turnaround clinicians rely on for treatment decisions. The shift: replacing a patchwork of single-gene and translocation assays with one integrated DNA/RNA NGS workflow, covering 500+ genes and 250+ translocations across both myeloid and lymphoid disease in a single run, powered by automated library preparation and the SOPHiA DDM™ platform's AI-driven variant analysis.
At the conclusion of this session, participants will be able to:
Presenter
Prof. Klaus Schmetterer, MD, PhD, heads the Cytogenetics Diagnostics section and the Molecular Biology in Hemato-Oncology Diagnostics section within the Department of Laboratory Medicine at the Medical University of Vienna (AKH Wien, Austria), roles he holds since 2022 and 2025 respectively. He also holds a tenure-track position at the university since 2021.
His path into hemato-oncology diagnostics began in immunology: he completed his Master's and PhD research in the laboratory of Winfried Pickl, MD, at the Institute of Immunology, Medical University of Vienna, earning his MD in 2010 and his PhD in Molecular Biology in 2011. He joined the Department of Laboratory Medicine in 2012 for his residency and completed it in 2018 as a board-certified specialist in Laboratory Medicine.
BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights
“We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%,” said Ross Muken, Chief Executive Officer of SOPHiA GENETICS. “Strong revenue performance was driven by 60% volume growth in the U.S., 70% volume growth in Liquid Biopsy, and accelerating growth in BioPharma. BioPharma growth is well-positioned to continue into 2027, as today we announce the signing of two companion diagnostic programs with AstraZeneca, the first ever in SOPHiA GENETICS' history."
Muken added, “As I step into the role of CEO, my focus will be on converting our world-class AI platform, a hard-won global network, and a decade of scientific credibility into accelerating, profitable growth for years to come. To achieve these goals, we strengthened our balance sheet with an oversubscribed $57.5 million public offering in Q2, providing sufficient capital to reach our business objectives and invest in long-term growth.”
Business Highlights
Expanding with existing customers
Landing new customers to fuel future growth
Accelerating growth in the U.S. market
Scaling growth with new applications
Developing partnerships to fuel growth
Building BioPharma partnerships
Driving operational excellence
2026 Financial Outlook
Based on information as of today, SOPHiA GENETICS expects:
Earnings Call and Webcast Information
SOPHiA GENETICS will host a conference call and live webcast to discuss the second quarter 2026 results on Tuesday, August 4, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
Non-IFRS Financial Measures
Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-IFRS measure) to loss for the period (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying depreciation expense, amortization of capitalized research & development expenses and intangible assets, interest income, interest expense, fair value adjustments on warrants, income taxes, foreign exchange gains or losses, share-based compensation expenses, social charges on share-based compensation, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs, litigation expenses and restructuring costs that are necessary for such reconciliation.
To provide investors with additional information regarding the company’s financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:
These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.
These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS’ results as reported under IFRS. Some of these limitations are:
Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.
The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.
Presentation of Constant Currency Revenue
SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period.
The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.
The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contact:
Kellen Sanger
[email protected]
[email protected]
SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Loss
(Amounts in USD thousands, except per share data)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $ 23,310 | $ 18,323 | $ 44,998 | $ 36,102 |
| Cost of revenue | (8,249) | (6,053) | (15,188) | (11,624) |
| Gross profit | 15,061 | 12,270 | 29,810 | 24,478 |
| Research and development costs | (8,731) | (8,493) | (18,191) | (17,611) |
| Selling and marketing costs | (11,186) | (10,034) | (19,999) | (17,568) |
| General and administrative costs | (15,202) | (12,301) | (28,961) | (23,901) |
| Other operating income, net | 5 | 66 | 5 | 74 |
| Operating loss | (20,053) | (18,492) | (37,336) | (34,528) |
| Interest income | 231 | 419 | 520 | 869 |
| Interest expense | (1,620) | (559) | (3,287) | (1,218) |
| Fair value adjustments on warrant obligations | (317) | 58 | (409) | 20 |
| Foreign exchange losses, net | (519) | (3,078) | (835) | (3,677) |
| Loss before income taxes | (22,278) | (21,652) | (41,347) | (38,534) |
| Income tax expense | (78) | (762) | (331) | (1,265) |
| Loss for the period | (22,356) | (22,414) | (41,678) | (39,799) |
| Attributable to the owners of the parent | (22,356) | (22,414) | (41,678) | (39,799) |
| Basic and diluted loss per share | $ (0.30) | $ (0.33) | $ (0.58) | $ (0.59) |
SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Comprehensive Loss
(Amounts in USD thousands)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Loss for the period | $ (22,356) | $ (22,414) | $ (41,678) | $ (39,799) |
| Other comprehensive (loss) income: | ||||
| Items that may be reclassified to statement of loss | ||||
| Currency translation adjustments | (81) | 9,016 | (611) | 11,602 |
| Total items that may be reclassified to statement of loss | (81) | 9,016 | (611) | 11,602 |
| Items that will not be reclassified to statement of loss (net of tax) | ||||
| Remeasurement of defined benefit plans | 317 | 46 | 440 | 93 |
| Total items that will not be reclassified to statement of loss | 317 | 46 | 440 | 93 |
| Other comprehensive (loss) income for the period | $ 236 | $ 9,062 | $ (171) | $ 11,695 |
| Total comprehensive loss for the period | $ (22,120) | $ (13,352) | $ (41,849) | $ (28,104) |
| Attributable to owners of the parent | $ (22,120) | $ (13,352) | $ (41,849) | $ (28,104) |
SOPHiA GENETICS SA
Interim Condensed Consolidated Balance Sheets
(Amounts in USD thousands)
(Unaudited)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 107,665 | $ 70,289 |
| Accounts receivable | 14,112 | 15,001 |
| Inventory | 7,084 | 6,351 |
| Prepaids and other current assets | 8,429 | 7,438 |
| Total current assets | 137,290 | 99,079 |
| Non-current assets | ||
| Property and equipment | 4,903 | 5,665 |
| Intangible assets | 36,163 | 35,891 |
| Right-of-use assets | 11,039 | 12,382 |
| Deferred tax assets | 1,769 | 1,831 |
| Other non-current assets | 7,195 | 8,183 |
| Total non-current assets | 61,069 | 63,952 |
| Total assets | $ 198,359 | $ 163,031 |
| Liabilities and equity | ||
| Current liabilities | ||
| Accounts payable | $ 11,904 | $ 8,960 |
| Accrued expenses | 18,699 | 20,736 |
| Deferred contract revenue | 15,616 | 16,720 |
| Lease liabilities, current portion | 2,720 | 2,700 |
| Warrant obligations | 2,144 | 1,412 |
| Total current liabilities | 51,083 | 50,528 |
| Non-current liabilities | ||
| Borrowings | 47,999 | 47,733 |
| Lease liabilities, net of current portion | 11,108 | 12,587 |
| Defined benefit pension liabilities | 3,822 | 4,162 |
| Other non-current liabilities | 1,229 | 876 |
| Total non-current liabilities | 64,158 | 65,358 |
| Total liabilities | 115,241 | 115,886 |
| Equity | ||
| Share capital | 4,814 | 4,814 |
| Share premium | 542,657 | 473,675 |
| Treasury shares | (183) | (1,218) |
| Other reserves | 96,784 | 89,150 |
| Accumulated deficit | (560,954) | (519,276) |
| Total equity | 83,118 | 47,145 |
| Total liabilities and equity | $ 198,359 | $ 163,031 |
SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Cash Flows
(Amounts in USD thousands)
(Unaudited)
| Six months ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Loss before tax | $ (41,347) | $ (38,534) |
| Adjustments for non-monetary items | ||
| Depreciation | 2,159 | 1,927 |
| Amortization | 3,499 | 2,740 |
| Finance expense, net | 3,354 | 4,037 |
| Fair value adjustments on warrant obligations | 409 | (20) |
| Expected credit loss allowance increase (reversal) | 40 | 252 |
| Share-based compensation | 7,805 | 8,191 |
| Movements in provisions and pensions | 440 | 304 |
| Research tax credit | (441) | (528) |
| Working capital changes | ||
| Decrease (increase) in accounts receivable | 589 | (1,298) |
| Decrease (increase) in prepaids and other assets | 628 | 934 |
| Decrease (increase) in inventory | (1,123) | 362 |
| Increase (decrease) in accounts payables, accrued expenses, deferred contract revenue, and other liabilities | 1,227 | 2,815 |
| Cash used in operating activities | (22,761) | (18,818) |
| Income tax paid | (51) | (146) |
| Net cash flows used in operating activities | (22,812) | (18,964) |
| Investing activities | ||
| Purchase of property and equipment | (1,026) | (130) |
| Acquisition of intangible assets | — | (87) |
| Capitalized development costs | (4,541) | (3,250) |
| Interest received | 520 | 876 |
| Net cash flow used in investing activities | (5,047) | (2,591) |
| Financing activities | ||
| Proceeds from exercise of share options | 1,233 | 115 |
| Interest paid | (2,715) | (1,240) |
| Proceeds from borrowings, net of transaction costs | — | 34,563 |
| Proceeds from sale of common stock in at-the-market offering, net of transaction costs | 15,667 | — |
| Proceeds from sale of common stock in follow-on offering, net of transaction costs | 54,048 | — |
| Payments of principal portion of lease liabilities | (1,201) | (889) |
| Net cash flow provided by/(used in) financing activities | 67,032 | 32,549 |
| Increase (decrease) in cash and cash equivalents | 39,173 | 10,994 |
| Effect of exchange differences on cash balances | (1,797) | 3,602 |
| Cash and cash equivalents at beginning of the period | 70,289 | 80,226 |
| Cash and cash equivalents at end of the period | $ 107,665 | $ 94,822 |
SOPHiA GENETICS SA
Reconciliation of IFRS Net Loss to Adjusted EBITDA
(Amounts in USD thousands)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| IFRS loss for the period | $ (22,356) | $ (22,414) | $ (41,678) | $ (39,799) |
| Exclude the impact of: | ||||
| Depreciation | $ 1,080 | $ 942 | $ 2,159 | $ 1,927 |
| Amortization(3)(4) | 1,827 | 1,428 | 3,499 | 2,740 |
| Interest income | (231) | (419) | (520) | (869) |
| Interest expense | 1,620 | 559 | 3,287 | 1,218 |
| Fair value adjustments on warrant obligations | 317 | (58) | 409 | (20) |
| Foreign exchange losses, net | 519 | 3,078 | 835 | 3,677 |
| Income tax expense | 78 | 762 | 331 | 1,265 |
| Share-based compensation expense(1) | 4,492 | 4,356 | 7,805 | 8,191 |
| Social charges related to share-based compensation(7) | 1,240 | (360) | 2,308 | (5) |
| Non-cash pension expense(2) | 72 | 89 | 163 | 175 |
| Transaction costs(5) | 123 | — | 291 | — |
| Litigation expenses(6) | 1,130 | — | 1,819 | — |
| Restructuring costs(8) | 1,255 | — | 1,255 | — |
| Adjusted EBITDA | $ (8,834) | $ (12,037) | $ (18,037) | $ (21,500) |
SOPHiA GENETICS SA
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
(Amounts in USD thousands, except for %)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||||
|---|---|---|---|---|---|---|
| 2026 | 2025 | Growth | 2026 | 2025 | Growth | |
| IFRS revenue | $ 23,310 | $ 18,323 | 27% | $ 44,998 | $ 36,102 | 25% |
| Current period constant currency impact | (454) | — | (1,936) | — | ||
| Constant currency revenue | $ 22,856 | $ 18,323 | 25% | $ 43,062 | $ 36,102 | 19% |
SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
(Amounts in USD thousands, except percentages)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $ 23,310 | $ 18,323 | $ 44,998 | $ 36,102 |
| Cost of revenue | (8,249) | (6,053) | (15,188) | (11,624) |
| Gross profit | $ 15,061 | $ 12,270 | $ 29,810 | $ 24,478 |
| Amortization of capitalized research and development expenses(3) | 1,757 | 1,357 | 3,359 | 2,598 |
| Adjusted gross profit | $ 16,818 | $ 13,627 | $ 33,169 | $ 27,076 |
| Gross profit margin | 64.6% | 67.0% | 66.2% | 67.8% |
| Amortization of capitalized research and development expenses(3) | 7.5% | 7.4% | 7.5% | 7.2% |
| Adjusted gross profit margin | 72.1% | 74.4% | 73.7% | 75.0% |
BOSTON and ROLLE – August 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS’s decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.
As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic. In addition, the company will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer.
“A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch. We believe these programs are what that future looks like in practice. Bringing the right therapy to the right patient, in any country and any laboratory, is the work that will define the next generation of precision medicine,” said Ross Muken, CEO, SOPHiA GENETICS.
By combining accurate biomarker detection with rapid deployment, SOPHiA GENETICS aims to shorten the distance between a new therapy and the patients who need it. Through its global data-driven platform, insights generated from patient populations can help advance informed clinical decision-making across healthcare systems. This vision of connected, data-driven medicine underpins these programs, with the goal of expanding access to innovative treatments and improving outcomes for patients worldwide.
About SOPHiA GENETICS Companion Diagnostics
SOPHiA GENETICS end-to-end diagnostic capabilities span the drug development and launch continuum:
SOPHiA GENETICS’s technology-agnostic, cloud-based platform lets healthcare institutions run the same validated, AI-powered analysis locally, while sharing and benefiting from the collective intelligence of a global network of more than 1,000 connected institutions across over 75 countries. For a pharmaceutical partner preparing a global launch, that means a companion diagnostic that can be available in the local lab on day one of drug approval.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media and Investor Contact
Kellen Sanger
[email protected]
[email protected]
Clonal hematopoiesis of indeterminate potential (CHIP) is an increasingly recognized challenge in liquid biopsy analysis. Somatic variants arising in hematopoietic progenitor cells can appear in cell-free DNA (cfDNA) analyses, mimicking tumor-derived signals and complicating result interpretation. Correctly assigning these variants is critical – both to avoid false tumor calls and to capture CHIP's emerging role as an independent biomarker for cancer risk and outcomes.
MSK-ACCESS® powered with SOPHiA DDM™ incorporates matched white blood cell (WBC) DNA sequencing to systematically distinguish CHIP and germline variants from true tumor-derived signals. In this poster presentation, Florian Klemm shares findings from a multicenter, retrospective study evaluating CHIP detection across different cfDNA analysis approaches in individuals with colorectal, prostate, pancreatic, and breast cancer. This research was conducted in collaboration with Synnovis, UK.
Watch to discover:
Presenter
Florian Klemm, Technical Product Manager Expert Lead, SOPHiA GENETICS, Rolle, Switzerland
Dr. Florian Klemm is a physician-scientist and tumor immunologist with deep expertise in next‑generation sequencing (NGS), liquid biopsy technologies, and translational oncology. As a Technical Product Manager Expert Lead at SOPHiA GENETICS, he drives the product design of decentralized cfDNA NGS solutions. Most notably, he has led the development of MSK‑ACCESS® powered with SOPHiA DDM™ where he led cross‑functional teams spanning assay development, bioinformatics, tertiary annotation, and software.
With more than a decade of research experience across the Ludwig Institute for Cancer Research at the University of Lausanne, Switzerland, Memorial Sloan Kettering Cancer Center, New York, USA and the University of Göttingen, Germany, Florian has an extensive track record applying NGS, multidimensional genomics, spatial tissue analysis, and large‑scale datasets to advance understanding of tumor biology and tumor–immune interactions. His first‑author publication in Cell (2020) highlights his contributions to mapping immune cell states in brain malignancies. He is passionate about bridging clinical insight, high‑throughput technologies, and data‑driven approaches to deliver impactful solutions that improve patient outcomes.
Copy number variants (CNVs) are increasingly recognized as clinically significant biomarkers across a wide range of tumor types, with emerging evidence supporting their role in prognosis, therapeutic stratification, and disease characterization. Despite advances in CGP, accurate CNV detection and interpretation in solid tumors remains challenging, owing to tumor heterogeneity, assay complexity, and inconsistent analytical approaches.
In this webinar, participants will explore current challenges and considerations associated with CNV detection and interpretation in precision oncology research. Through real-world examples and discussion of CGP strategies, the webinar will examine approaches for improving scalability, consistency, and confidence in biomarker characterization.
Join us to gain insight into evolving approaches for CGP and the role of CNV analysis in advancing precision oncology research.
At the conclusion of this session, participants will be able to:
Presenter
Dr. Rami Mahfouz MD, MPH, IFCAP
Professor of Molecular Pathology, Head of Division of Clinical Pathology, Director of Molecular Diagnostics Laboratory, American University of Beirut, Lebanon
Dr. Lina Li, PhD, MBA
Director of Product for Solid Tumors, SOPHiA GENETICS
Evidence-based interpretation of oncogenic variants represents one of the most demanding and time-consuming tasks carried out by clinical laboratories today. The volume of emerging clinical evidence,and the multiplication of evidence sources across fragmented platforms, combined with the need fortimely and accurate reporting, places considerable pressure on laboratory workflows and the professionals who lead them.
In this webinar, Dr. Sara Allegrini, Head of Molecular Pathology at TomaLab, one of the largest genetic laboratories in Italy, examines how the integration of OncoPortal™ Knowledge Base within SOPHiADDM™ has reshaped their approach to oncology variant interpretation. The session draws on Dr.Allegrini's real-world experience to trace the laboratory's workflow evolution, from their previous use of OncoPortal™ Plus as a standalone module to the adoption of a fully integrated solution.
Dr. Allegrini will share first-hand insights into the challenges of evidence-based interpretation at scale,the criteria that guided TomaLab's adoption of OncoPortal™ Knowledge Base, and the impact observedon reporting efficiency and interpretation confidence. The session will also illustrate the value of the platform through concrete case examples, including rare alterations and complex findings where accessto curated, current evidence proved decisive.
At the conclusion of this session, participants will be able to:
Presenter
Dr. Sara Allegrini, Molecular Biologist, Leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory
Dr. Sara Allegrini is a molecular biologist and expert in precision oncology, currently leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory. With over a decade of experience in molecular diagnostics and cancer genomics, she plays a key role in integrating advanced technologies such as next-generation sequencing into routine clinical practice.
She holds a PhD in Molecular Medicine and a specialization in Clinical Pathology, complemented by a recent advanced Master’s degree in Molecular Pathology and Molecular Tumor Boards. Her expertise spans next-generation sequencing, molecular oncology, and precision medicine, with a strong focus on the interpretation of somatic variants in cancer. Her work focuses on the clinical interpretation of somatic variants and their application in personalized cancer treatment.
She has a strong background in translational research, bridging the gap between laboratory innovation and patient care. She is passionate about advancing precision medicine and improving diagnostic strategies in oncology.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.